Lopinavir-ritonavir: A new protease inhibitor

Pharmacotherapy

Volumn 21, Issue 11, 2001, Pages 1352-1363

  Mangum, E M ^a   Graham, K K ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABY 378; AMPRENAVIR; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ATORVASTATIN; ATOVAQUONE; CALCIUM CHANNEL BLOCKING AGENT; CLARITHROMYCIN; DEXAMETHASONE; DISULFIRAM; EFAVIRENZ; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LAMIVUDINE; LAXATIVE; LOPERAMIDE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIFABUTIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SIMVASTATIN; STAVUDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANTIVIRAL ACTIVITY; ASTHENIA; CHILD; CLINICAL TRIAL; CROSS RESISTANCE; DIARRHEA; DRUG ABSORPTION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; DRUG PROGRAM; DRUG RESISTANCE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LIVER TOXICITY; NAUSEA; PANCREATITIS; REVIEW; VOMITING;

EID: 0035160110     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.17.1352.34419     Document Type: Review

References (35)

1. ABT-378, A highly potent inhibitor of the human immunodeficiency virus protease
2. Multiple-dose pharmacokinetics (PK) of ABT-378/ritonavir (ABT-378/r) in HIV+ subjects
3. In vitro metabolism of the HIV-1 protease inhibitor ABT-378: Species comparison and metabolite identification
4. Concomitant administration of ABT-378/ritonavir results in a clinically important pharmacokinetic interaction with atorvastatin but not pravastatin
5. Pharmacokinetic interactions between protease inhibitors and selected HMG-CoA reductase inhibitors
6. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
7. A pharmacokinetic study to investigate the influence of efavirenz on a BID indinavir/ritonavir regimen (800/100 mg) in healthy volunteers
8. In vitro selection and characterization of human immunodeficiency virus type 1 I variants with increased resistance to ABT-378, a novel protease inhibitor
9. Definition of genotypic breakpoints for ABT-378/ritonavir for use in the interpretation of HIV resistance testing
10. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy
11. Genotypic and phenotypic analysis of viral isolates from subjects with detectable viral load on therapy with ABT-378/ritonavir
12. Kaletra (ABT-378/Ritonavir) in antiretroviral naive HIV+ patients: Follow-up beyond two years and viral load suppression below 3 copies/ml
13. A Phase III, randomized, double-blind trial of Kaletra (ABT-378/r) + Stavudine (d4T) and Lamivudine (3TC) vs. Nelfinavir + d4T/3TC
14. Absence of resistance to Kaletra (ABT-378/r) observed through 48 weeks of therapy in antiretroviral-naive subjects
15. Durable suppression of HIV+ RNA after two years of Kaletra (ABT-378/ritonavir) therapy in single protease inhibitor experienced patients
16. Kaletra (ABT-378/ritonavir) and Efavirenz: 48-week safety/efficacy evaluation in multiple PI experienced patients
17. Kaletra (ABT-378/r) and Efavirenz: One-year safety/efficacy evaluation and phenotypic breakpoints in multiple-PI-experienced patients
18. Initial efficacy results from the Kaletra (formerly known as ABT-378/r) early-access program
19. Analysis of safety data from ABT-378/ritonavir in two Phase II clinical trials
20. Lipid profiles in patients on ritonavir/indinavir-containing salvage regimens
21. Efficacy of amprenavir 600 mg plus low-dose rigonavir in clinical practice
22. Ritonavir, saquinavir, and nevirapine as salvage regimen in antiretroviral experienced patients in a county clinic: 95-week follow-up
23. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities
24. Atorvastatin for protease inhibitor-related hyperlipidaemia
25. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients
26. A randomized open label trial of dietary advice with or without pravastatin for the management of protease inhibitor-associated hypercholesterolemia
27. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection
28. Validation of a dyslipidemia algorithm in HIV-positive patients